TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A post hoc analysis of the WAHA randomized trial found that older adults assigned to eat walnuts daily had total serum IgG levels about 6% higher than controls after two years. The study did not establish that this change improves immunity or prevents cardiovascular disease, and it found no significant walnut-related effects on several other measured immune markers.
A secondary analysis of a two-year randomized trial found that older adults assigned to eat walnuts daily had total IgG levels about 6% higher than participants in a walnut-excluding control group. Published in JACC Advances, the analysis examined immune biomarkers, but it did not show that the IgG difference improves health or prevents heart disease.
The analysis drew on the Walnuts and Healthy Aging (WAHA) trial, which enrolled 708 cognitively healthy adults aged 63 to 79 in the United States and Spain. Participants were randomly assigned to a walnut-based or walnut-excluding diet for two years. The walnut group was asked to eat 30 to 60 grams daily, about 15% of daily energy intake.
Researchers tested blood samples collected at the start and after two years from 474 participants: 240 in the walnut group and 234 controls. They measured total immunoglobulin G (IgG) and immunoglobulin M (IgM), antibodies directed at modified LDL, and circulating malondialdehyde-modified LDL (MDA-LDL). These immune measures were not the original trial’s main outcomes, which concerned cognitive function and retinal integrity.
The higher total IgG result appeared across participants from both countries, but the country-specific findings differed: the analysis detected an 11% higher IgG level among U.S. participants assigned walnuts and no statistically significant intervention effect in Spain. Walnut consumption was not significantly associated with changes in total IgM, MDA-LDL, or either measured class of MDA-LDL-specific antibodies. Total IgG and IgM, as well as MDA-LDL-specific IgM antibodies, declined over time in both groups.
What the IgG Finding Can Tell Us
IgG is a common antibody class and one measure of the body’s humoral immune system. A difference in total IgG can indicate a change in a circulating immune marker, but it does not by itself show whether the immune system is functioning better, whether a person is less likely to become ill, or whether cardiovascular risk has changed. The study did not test those outcomes as consequences of the IgG result.
The researchers examined these markers because atherosclerosis involves inflammation and the buildup of plaque in blood vessels. Oxidized forms of LDL can prompt immune responses, and some research has linked particular antibody levels with cardiovascular measures. But associations between antibodies and outcomes do not establish that changing those antibodies through diet will change disease risk. The present result is a biomarker finding, not evidence that walnuts treat or prevent a condition.
The lack of significant effects on MDA-LDL and the measured MDA-LDL-specific antibodies also limits what can be concluded about the proposed pathway. The overall IgG difference may help guide future studies, but readers should not interpret it as a demonstrated immune or heart-health benefit.
Products Worth Considering
KitchenAid 8-Cup Grain and Rice Cooker with Integrated Scale, Black Matte
Vitamix 5200 Professional-Grade Blender, 64 oz. Container, Black
Ninja DCT451 12-in-1 Smart Double Oven with FlexDoor, Stainless Steel
As an affiliate, we earn on qualifying purchases.
How the WAHA Analysis Was Conducted
The WAHA trial was conducted among older adults in Spain and the United States. It excluded people who already ate more than two servings of tree nuts a week, as well as people using certain supplements, including soy lecithin, fish oil, or flaxseed oil. Participants attended follow-up assessments every two months, where researchers monitored factors including weight, tolerance, adherence, and medication use.
This report is a post hoc analysis: the original trial was designed to assess cognitive and retinal outcomes, while the immune-marker questions were examined later. The researchers adjusted their analyses for factors including age, sex, smoking, study center, cholesterol, body mass index, hypertension, and diabetes. In Spanish participants, red blood cell alpha-linolenic acid levels rose substantially in the walnut group and fell in controls, a result the report said supported adherence to the assigned diets.
Prior research has connected higher total IgG or certain antibodies against oxidized LDL with cardiovascular measures, but findings have not been consistent for MDA-LDL-specific IgG. Those earlier associations provide a reason to study the markers; they do not establish the health meaning of the difference observed in WAHA.
“The clinical implications remain uncertain.”
— The study authors, as summarized in the report
What the Immune Marker Cannot Show
The analysis does not establish why total IgG was higher in the walnut group or whether the difference has any effect on participants’ health. It did not show fewer infections, improved immune function, or fewer cardiovascular events attributable to walnuts. It also remains unclear why a statistically significant effect appeared in the U.S. group but not in Spain; the study report notes substantial baseline differences in immune-marker levels between the centers.
Only 474 of the 708 trial participants had samples included in this biomarker analysis, and the immune outcomes were assessed after the original trial was designed. The findings therefore need to be interpreted as evidence about measured blood markers in this study population, not as a direct prediction of health outcomes for individuals. The results do not determine whether other doses, longer periods, or different populations would show the same pattern.
Further Studies Must Test Health Outcomes
The findings provide a basis for further research into whether walnut intake influences immune markers and whether any such changes relate to cardiovascular health or other clinical outcomes. Future studies could test the IgG result in populations beyond cognitively healthy older adults and examine why the country-specific results differed.
Until research measures meaningful health outcomes and clarifies the role of the IgG change, the study does not support a claim that walnuts boost immunity or prevent heart disease. The next step is to determine whether this biomarker association is reproducible and clinically relevant.
Key Questions
What did the walnut study find?
A post hoc analysis found that participants assigned to eat 30 to 60 grams of walnuts daily had total IgG levels about 6% higher than controls after two years. The analysis did not find significant walnut-related effects on total IgM, MDA-LDL, or the measured MDA-LDL-specific antibodies.
Does higher IgG mean walnuts improve immunity?
Not based on this study alone. Total IgG is an immune-system marker, but the analysis did not show that the higher level improved immune function or reduced illness. The authors said the clinical implications remain uncertain.
Did the study show that walnuts lower heart-disease risk?
No. It examined blood biomarkers and did not establish that the IgG difference led to fewer cardiovascular events or less atherosclerosis.
Were the findings the same in Spain and the United States?
No statistically significant intervention effect was detected in Spain. In the U.S. participants, total IgG was 11% higher in the walnut group than in controls after two years. The reason for the difference between centers is not established.
How many participants were included in the immune-marker analysis?
Researchers analyzed baseline and two-year blood samples from 474 participants in the WAHA trial: 240 assigned to walnuts and 234 in the control group.
Source: news-medical.net
